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increasingly applied in clinical trials and vaccines. Their success partially depends on accurate delivery 
of cells to target organs or migration to lymph nodes. Delivery and subsequent migration of cells to 
regional lymph nodes is essential for effective stimulation of the immune system. Thus, the design of an 
optimal DC therapy would be improved by optimizing technologies for monitoring DC trafficking. 
Magnetic resonance imaging (MRI) represents a powerful tool for non-invasive imaging of DC 
migration in vivo. Domestic pigs are closely related to humans and represent an excellent animal 
model for immunological studies. The aim of this study was to investigate the possibility using pigs as 
models for DC tracking in vivo. 
Porcine monocyte derived DC (MoDC) culture with superparamagnetic iron oxide (SPIO) particles was 
standardized on the basis of SPIO concentration and culture viability. Phenotype, cytokine production 
and mixed lymphocyte reaction assay confirmed that porcine SPIO-MoDC culture were similar to mock 
MoDCs and fully functional in vivo. Alike, similar patterns were obtained in human MoDCs. After 
subcutaneous inoculation in pigs, porcine SPIO-MoDC migration to regional lymph nodes was detected 
by MRI and confirmed by Perls staining of draining lymph nodes. Moreover, after one dose of virus-like 
particles-pulsed MoDCs specific local and systemic responses were confirmed using ELISPOT IFN-γ in 
pigs. In summary, the results in this work showed that after one single subcutaneous dose of pulsed 
MoDCs, pigs were able to elicit specific local and systemic immune responses. Additionally, the 
dynamic imaging of MRI-based DC tracking was shown using SPIO particles. This proof-of-principle 
study shows the potential of using pigs as a suitable animal model to test DC trafficking with the aim of 
improving cellular therapies. 
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Cellular therapies using immune cells and in particular dendritic cells (DCs) are being 
increasingly applied in clinical trials and vaccines. Their success partially depends on 
accurate delivery of cells to target organs or migration to lymph nodes. Delivery and 
subsequent migration of cells to regional lymph nodes is essential for effective 
stimulation of the immune system. Thus, the design of an optimal DC therapy would be 
improved by optimizing technologies for monitoring DC trafficking. Magnetic 
resonance imaging (MRI) represents a powerful tool for non-invasive imaging of DC 
migration in vivo. Domestic pigs share similarities with humans and represent an 
excellent animal model for immunological studies. The aim of this study was to 
investigate the possibility using pigs as models for DC tracking in vivo. 
Porcine monocyte derived DC (MoDC) culture with superparamagnetic iron oxide 
(SPIO) particles was standardized on the basis of SPIO concentration and culture 
viability. Phenotype, cytokine production and mixed lymphocyte reaction assay 
confirmed that porcine SPIO-MoDC culture were similar to mock MoDCs and fully 
functional in vivo. Alike, similar patterns were obtained in human MoDCs. After 
subcutaneous inoculation in pigs, porcine SPIO-MoDC migration to regional lymph 
nodes was detected by MRI and confirmed by Perls staining of draining lymph nodes. 
Moreover, after one dose of virus-like particles-pulsed MoDCs specific local and 
systemic responses were confirmed using ELISPOT IFN-γ in pigs. In summary, the 
results in this work showed that after one single subcutaneous dose of pulsed MoDCs, 
pigs were able to elicit specific local and systemic immune responses. Additionally, the 
dynamic imaging of MRI-based DC tracking was shown using SPIO particles. This 
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test DC trafficking with the aim of improving cellular therapies. 
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Highlights: 1 
 Human or pig dendritic cells pulsed with superparamagnetic iron oxide particles 2 
did not alter their phonotypic and functional properties in vitro in the 3 
experimental conditions tested in this work.   4 
 After subcutaneous inoculation in pigs, porcine SPIO-MoDC migration to 5 
regional lymph nodes was detected by MRI and confirmed by Perls staining of 6 
draining lymph nodes.  7 
 Only one dose of virus-like particles-pulsed MoDCs in pigs was able to induce 8 
specific local and systemic responses. 9 
 This proof-of-principle study shows the potential of using pigs as a suitable 10 
animal model to test DC trafficking with the aim of improving cellular therapies. 11 
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Abstract 28 
 29 
Cellular therapies using immune cells and in particular dendritic cells (DCs) are being 30 
increasingly applied in clinical trials and vaccines. Their success partially depends on 31 
accurate delivery of cells to target organs or migration to lymph nodes. Delivery and 32 
subsequent migration of cells to regional lymph nodes is essential for effective 33 
stimulation of the immune system. Thus, the design of an optimal DC therapy would be 34 
improved by optimizing technologies for monitoring DC trafficking. Magnetic 35 
resonance imaging (MRI) represents a powerful tool for non-invasive imaging of DC 36 
migration in vivo. Domestic pigs share similarities with humans and represent an 37 
excellent animal model for immunological studies. The aim of this study was to 38 
investigate the possibility using pigs as models for DC tracking in vivo. 39 
Porcine monocyte derived DC (MoDC) culture with superparamagnetic iron oxide 40 
(SPIO) particles was standardized on the basis of SPIO concentration and culture 41 
viability. Phenotype, cytokine production and mixed lymphocyte reaction assay 42 
confirmed that porcine SPIO-MoDC culture were similar to mock MoDCs and fully 43 
functional in vivo. Alike, similar patterns were obtained in human MoDCs. After 44 
subcutaneous inoculation in pigs, porcine SPIO-MoDC migration to regional lymph 45 
nodes was detected by MRI and confirmed by Perls staining of draining lymph nodes. 46 
Moreover, after one dose of virus-like particles-pulsed MoDCs specific local and 47 
systemic responses were confirmed using ELISPOT IFN-γ in pigs. In summary, the 48 
results in this work showed that after one single subcutaneous dose of pulsed MoDCs, 49 
pigs were able to elicit specific local and systemic immune responses. Additionally, the 50 
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dynamic imaging of MRI-based DC tracking was shown using SPIO particles. This 51 
proof-of-principle study shows the potential of using pigs as a suitable animal model to 52 
test DC trafficking with the aim of improving cellular therapies. 53 
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1. Introduction 76 
 77 
Immune cell therapies are being increasingly applied as therapeutic approach, 78 
predominantly, with the aim of stimulating immune responses against tumours, 79 
infectious diseases or to induce tolerance in autoimmunity (Hilkens and Isaacs, 2013). 80 
The success of these treatments will partially depend on accurate delivery of cells to 81 
target organs. Dendritic cells (DCs) have a crucial role in initiating and driving the 82 
immune responses, thus, antigen-loaded DC immunotherapy has been increasingly used 83 
in clinical trials (Ardon et al., 2012). Indeed, DCs are an attractive tool for therapeutic 84 
manipulation of the immune system and are currently tested for treatment of cancer 85 
(Aarntzen et al., 2012; Banchereau and Palucka, 2005; Figdor et al., 2004; Nestle et al., 86 
2005; Randolph et al., 2005; Schuler et al., 2003) or to ameliorate autoimmune diseases 87 
(Giannoukakis et al., 2011; Hilkens and Isaacs, 2013). Although the potential of DC 88 
therapy was largely demonstrated, vaccination efficiency needs continuous 89 
improvement. Factors influencing DC immunogenicity depend on the subset, 90 
maturation state, activation stimulus and optimal conditioning. Route, dosage and 91 
frequency of DC injections also need to be optimized (Figdor et al., 2004). Their 92 
migration from the site of injection to the draining lymph nodes represents a major 93 
requirement for their immunogenic function. Effective migration of injected DCs to the 94 
secondary lymphoid organs and an appropriate stimulation of the immune system 95 
remains an essential step for DC therapy (Baumjohann et al., 2006). 96 
In previous studies in human, ex vivo generated DCs have been administered by 97 
different routes: intradermally, intranodally, subcutaneously, intravenously, 98 
intralymphatically or using combination of these routes (Baumjohann and Lutz, 2006; 99 
de Vries et al., 2005; Wilgenhof et al., 2013). Currently, in the case of solid tumors 100 
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treatment, intradermal or subcutaneous administrations of DCs are most frequently used 101 
followed by intravenous and intranodal injection (Verdijk et al., 2009). Nevertheless, 102 
the optimal route of administration for each DC therapy is not well established. In 103 
addition, the efficiency of DC migration to the lymph nodes is rather low (up to 4% of 104 
injected DCs migrate to the draining lymph nodes) (Verdijk et al., 2009). Thus, 105 
designing an optimal DC therapy would therefore be facilitated by technologies for 106 
monitoring DC trafficking in vivo and by efficient monitoring of lymph node homing by 107 
a non-invasive method (Baumjohann et al., 2006).  108 
Recent development of new methods to follow DC migration by non-invasive imaging 109 
modalities such as scintigraphy, PET or magnetic resonance or bioluminescence 110 
imaging have gained attraction because of their potential clinical applicability in human 111 
(Baumjohann and Lutz, 2006). Magnetic resonance imaging (MRI) of cells labelled 112 
with magnetically visible contrast agents after either direct injection or local or 113 
intravenous infusion has the potential to fulfil this goal. MRI is well suited as an 114 
imaging modality for non-invasive cell tracking because of its tissue characterization, 115 
excellent image quality, and high spatial resolution, although nuclear imaging is more 116 
sensitive. In general terms, MRI benefits are: lack of ionizing radiation, high spatial 117 
resolution, flexible image contrast and the ability to assess regional function, perfusion 118 
and necrosis (Rogers et al., 2006). Thus, MRI represents a sophisticated tool for non-119 
invasive imaging of DC migration in vivo (Baumjohann and Lutz, 2006). 120 
Iron oxide particles are part of a class of superparamagnetic MRI contrast agents. These 121 
particles range in size from tens of nanometers in diameter (ultrasmall 122 
superparamagnetic iron oxide (USPIO)), to 100 nm (superparamagnetic iron oxide 123 
(SPIO)) (Bulte and Kraitchman, 2004; Hoehn et al., 2007; Rogers et al., 2006). The 124 
relation of particle size to the rate of endocytosis was shown for in vitro human 125 
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monocytes by simple incubation of SPIO particles Endorem® (Guerbet, Villepinte, 126 
France) (Metz et al., 2004). SPIO phagocytic uptake is mediated by scavenger receptor 127 
SR-A (Raynal et al., 2004) and SPIO (Endorem®) show higher uptake rates than 128 
smaller particles (20-40) (Baumjohann et al., 2006). DCs are another cell type that can 129 
endocytose SPIO labels and can be used in MRI (Rogers et al., 2006). Different studies 130 
were performed in mice using MRI-based quantification of antigen presenting cell 131 
number in the draining lymph nodes (Baumjohann et al., 2006; Long et al., 2009) and  132 
Baumjohann et al. has shown that after subcutaneous injection of one million DCs there 133 
was still a clear MRI signal detectable in the draining lymph node that also correlated 134 
with immunohistological detection (Baumjohann et al., 2006).  135 
Virus-like particles (VLPs) present overall suitable characteristics for their uptake by 136 
DCs and subsequent processing and presentation to effector cells of the immune system 137 
(Crisci et al., 2012a). VLPs from rabbit hemorrhagic disease virus (RHDV) have shown 138 
to be good platforms for inducing immune responses against an inserted foreign epitope 139 
in mice (Barcena et al., 2004; Crisci et al., 2009; Luque et al., 2012). Recently, we 140 
successfully used chimeric RHDV-VLPs containing a well-known T-cell epitope 141 
derived from the 3A protein of foot-and-mouth disease virus (Cubillos et al., 2012) to 142 
induce specific T-cell responses in pigs (Crisci et al., 2012b). 143 
Domestic pigs share similarities in physiology, immunology, anatomy and size with 144 
humans, and represent an excellent animal model for immunological studies. Indeed, 145 
experiments in pigs are much more likely to be predictive of therapeutic treatments in 146 
humans than experiments in rodents. An exhaustive recent review (Meurens et al., 147 
2012) highlighted the importance of the pig model for human research and vaccine 148 
development. Recently, pigs have been used to investigate the in vivo tracking and their 149 
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therapeutic effect of autologous mesenchymal stem cells (MSCs) by intracoronary 150 
transplantation on myocardial infarction (MI) (Peng et al., 2013).  151 
Considering all these premises, the aim of this study was to investigate the possibility to 152 
use conventional pigs as a model for DC tracking in vivo by MRI. This study has shown 153 
that DCs could be labelled with SPIO particles without affecting their function. Porcine 154 
SPIO pulsed MoDCs migration to regional lymph nodes was detected. Additionally, 155 
SPIO pulsed MoDCs when incubated with the appropriate antigen (chimeric RHDV-156 
VLPs), were fully functional eliciting local and systemic responses in pigs. This is the 157 
first proof-of-principle report describing swine DC tracking in vivo and the efficacy of 158 
DC-based immunization.  159 
2. Materials and methods 160 
 161 
2.1 Porcine monocyte-derived and human monocyte-derived dendritic cell 162 
generation 163 
Porcine PBMCs were obtained from clinically healthy Large White X Landrace pigs of 164 
eight weeks of age. Porcine monocyte-derived dendritic cells (poMoDCs) where 165 
generated by a five-day protocol as previously described by (Carrasco et al., 2001; 166 
Silva-Campa et al., 2010). Briefly, freshly isolated PBMCs were placed in tissue culture 167 
flasks and incubated overnight at 37 °C in 5% CO2 to allow monocytes to adhere. Non-168 
adherent cells (peripheral blood lymphocytes, PBLs) were removed by washing with 169 
DMEM (Lonza) and frozen for use in mixed lymphocyte reaction (MLR) experiments. 170 
Adherent cells were cultured in complete DMEM (culture medium containing 2mM of 171 
L-glutamine (Invitrogen®, Barcelona, Spain), 100 U/ml of Polymixin B (Sigma–172 
Aldrich Quimica, S.A., Madrid, Spain), 10% of fetal calf serum (FCS) (Euroclone, 173 
Sziano, Italy) and 100 μg/ml of penicillin with 100 U/ml of streptomycin (Invitrogen®, 174 
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Barcelona, Spain) containing 40 ng/mL of recombinant porcine GM-CSF (R&D 175 
Systems) and 40 ng/mL of recombinant porcine IL-4 (R&D Systems) at 37 °C in 5% 176 
CO2. Cells were incubated for 5-6 days with cytokine-containing medium replacement 177 
on day 3. MoDCs were harvested on day 5 or 6 using cell dissociation enzyme-free 178 
Hank's-based buffer (Gibco® Cell Dissociation Buffer) and resuspended in complete 179 
DMEM. Stimuli were added at day 5 or 6 and mature and immature poMoDCs were 180 
analyzed by flow cytometry and cytokine ELISA. 181 
In order to generate human monocyte derived dendritic cells (huMoDCs), PBMCs from 182 
healthy donors were allowed to adhere 2 h at 37 ºC. The adherent monocytes were 183 
cultured in X-VIVO 15 medium (BioWhittaker, Lonza, Belgium) supplemented with 184 
2% AB human serum (Sigma-Aldrich, Spain), IL-4 (300 U/mL), and GM-CSF (450 185 
U/mL) (Both from Miltenyi Biotec, Madrid, Spain) for 7 days. The present study was 186 
approved by the Ethics Committee at the Hospital Clinic of Barcelona. Buffy coats were 187 
obtained from Banc de Sang i Teixits and written informed consent was obtained from 188 
all blood donors.  189 
 190 
2.2 Dendritic cell labelling with SPIO 191 
After 5 days poMoDCs were incubated overnight with SPIO particles (Endorem®, 11.2 192 
mg Fe/mL, Guebert, Aulnay-sous-Bois, France) at different iron concentrations ranging 193 
from 25 to 200 µg Fe/mL. Viability of cells was checked by trypan blue staining and by 194 
flow cytometry using LIFE/DEAD Fixable Dead Cell Stain Kit (Life Technologies), 195 
and FITC-conjugated Annexin V (Caltag Laboratories). Cells were stained during 15 196 
min at 4°C. Flow cytometry was performed using BD FACSCanto II, and data were 197 
analyzed with BD FACSDiva 6.1
TM
 software. 198 
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SPIO particles were added to huMoDCs at day 5, and huMoDCs phenotype and 199 
cytokine production was analysed at day 7 by flow cytometry and ELISA respectively. 200 
The same batch of SPIO particles was used in porcine and human DC studies. Human 201 
and porcine moDCs incubated with medium alone and without SPIO and/or stimuli 202 
were used as negative control and referred as Mock moDCs in the figures. 203 
 204 
2.3 Expression and purification of recombinant RHDV-VLPs 205 
In this study, native RHDV-VLPs and chimeric RHDV-VLPs harbouring a T-cell 206 
epitope derived from foot and mouth disease virus 3A protein (RHDV-3A-VLPs) were 207 
used, as previously reported (Crisci et al., 2012b). The recombinant VLPs were 208 
expressed in H5 insect cell-cultures infected with the corresponding recombinant 209 
baculoviruses and purified as previously described (Crisci et al., 2012b). 210 
 211 
2.4 Stimulation of poMoDCs and huMoDCs 212 
For in vitro studies, poMoDCs and SPIO-poMoDCs were stimulated with RHDV-VLPs 213 
(60 μg/mL) and LPS (10 μg/mL) (Lipopolysaccharides from Escherichia coli O111:B4, 214 
Sigma). Stimuli were plated with both poMoDCs after 6 days of culture (2.5x10
4 
215 
cells/50 μL/well) in 96-well plates. In SPIO-poMoDCs cultures, stimuli were plated the 216 
day after SPIO particles labelling. Before any analysis or inoculation, SPIO particles 217 
and stimuli excesses were thoroughly washed away.  218 
To generate mature huMoDCs, a maturation cocktail was added on day 6 for 24 h. This 219 
cocktail consisted of IL-1, IL-6 (both at 1000 IU/mL), TNF- (500 IU/mL) 220 
(CellGenix, Freiburg, Germany) and Prostaglandin E2 (PGE2, 10 µg/mL; Dinoprostona, 221 
Pfizer).   222 
 223 
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 224 
2.5 Flow cytometry analysis of poMoDCs and huMoDCs 225 
Flow cytometry analysis of poMoDCs was performed using an indirect labelling for 226 
CD172a (SIRP-α), SLA-I (MHC-I), SLA-II (MHC-II), CD4, CD11R3 (resemble 227 
CD11b), CD80/86 (B7-1/B7-2) and CD163 (scavenger R) and direct labelling for CD14 228 
(LPS R) and CD16 (FcγRIII) (reviewed in (Summerfield and McCullough, 2009) and 229 
(Ezquerra et al., 2009)). Unless specified below, reagents were derived from hybridoma 230 
supernatants. Briefly, poMoDCs were labelled during 1 h at 4ºC for each CD marker, 231 
using 30 µl of antibody solution. Anti-CD172a (SWC3, BA1C11), anti-SLAI (4B7/8), 232 
anti-SLAII (1F12), anti-CD4 (76-12-4), anti-CD11R3 (2F4/11), CTLA4-mIg (Ancell, 233 
Minnesota, USA), anti-CD163 (2A10/11), anti-CD14-FITC (MIL2, Serotec, bioNova 234 
cientifica, Madrid, Spain) and anti-CD16-FITC (G7, Serotec) were used. After 235 
incubation, they were washed with cold PBS with 2% FCS by centrifugation at 450 g, 236 
4ºC for 5 minutes. Then, the secondary antibody R-phycoerythryn anti-mouse IgG 237 
(Jackson ImmunoResearch, Suffolk, UK) diluted 1:300 was added when required. Cells 238 
were incubated for 1 h at 4ºC, they were washed as before and resuspended in PBS with 239 
2% FCS. Stained cells were acquired on Coulter EPICS XL-MCL cytometer and 240 
analysed by EXPO 32 ADC v.1.2 program.  241 
To characterize and compare the phenotype of the huMoDC populations the following 242 
mAbs or appropriate isotype controls were used: CD80, CD83, CD86 (BD-Biosciences) 243 
and FITC-labelled MHC class II (BD-Pharmingen). Primary antibodies were followed 244 
by staining with PE-labelled goat-anti-mouse (BD Biosciences). Flow cytometry was 245 
performed with FACSCanto II
™
 and analysed with FACSDiva software (BD 246 
Biosciences) and with WinMDI software (version 2.9). 247 
 248 
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2.6 Cytokine ELISAs 249 
Cytokine levels in conditioned cell supernatants were assayed by ELISA for porcine 250 
TNF- and IL-6 at 24 h. For each ELISA, triplicate wells of stimulated- or un-251 
stimulated-cells supernatants were used and all the results were analyzed with KC 252 
Junior Program (Bio Tek Instruments, Inc) using the filter Power Wave XS reader. For 253 
porcine TNF-α and IL-6 a DuoSet® ELISA Development system (R&D Systems, 254 
Abingdon, UK) was used following manufacturer’s instructions.  255 
IFN-γ (BD-Biosciences) from human MLR supernatants was analyzed by ELISA for 256 
human according to the manufacturer’s guidelines. 257 
 258 
2.7 Mixed lymphocyte reaction  259 
Mixed lymphocyte reaction (MLR) was evaluated by flow cytometry using the 260 
fluorescent dye carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes) for 261 
poMoDCs as previously described (Silva-Campa et al., 2010). The optimal conditions 262 
for the MLR were determined in preliminary experiments using different 263 
stimulator:responder cell ratios and different incubation times. PoMoDCs and SPIO-264 
poMoDCs were cultured with CFSE labelled-PBLs at a ratio 1:20 (MoDCs:PBLs). 265 
PoMoDCs and SPIO-poMoDCs were incubated with phytohaemagglutinin (PHA) (20 266 
μg/mL, Sigma) as postivie control or medium as negative control. Cultures were 267 
incubated at 37°C in 5% CO2 for 4 days. The percentage of proliferation was evaluated 268 
and values were represented as the mean of triplicate wells and representative of three 269 
different experiments, corresponding each one to a different animal. 270 
MLR was also tested for human DCs. Allogeneic T cells were co-cultured with 271 
huMoDCs differently generated in a 96-well microplate (in triplicates). For the 272 
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proliferation assay, a tritiated thymidine (1 µCi/well, Amersham, UK) was added to the 273 
cell cultures on day 6 and an incorporation assay was measured after 16 h.  274 
 275 
2.8 In vivo experimental designs 276 
At the age of 6-7 weeks, ten male conventional pigs (Large White x Landrace) were 277 
selected from a high health status farm located in the Northern part of Spain; these pigs 278 
were porcine reproductive and respiratory syndrome virus and porcine circovirus type 2 279 
negative and clinically healthy at the beginning of the experiment. Pigs received non-280 
medicated commercial feed ad libitum and had free access to drinking water. Animals 281 
were housed in an experimental farm (CEP, Torrelameau, Lleida, Spain) in different 282 
pens.  283 
Pigs were identified, ear-tagged and randomly distributed into four groups, namely A 284 
(n = 3), B (n = 3), C (n = 2) and D (n = 2) balanced by weight (range 17.5-23 kg). Pigs 285 
of group C remained untreated and were used as negative controls. Groups A and B 286 
were inoculated once subcutaneously (SC) into right inguinal zone with RHDV-3A-287 
VLP- and RHDV-VLP-pulsed MoDCs respectively. Group D was inoculated once with 288 
unpulsed MoDCs. Group A, B and D were inoculated with 1 mL of MoDCs (approx. 289 
5x10
5
 viable cells/mL/pig) 7 days after blood collection. Each pig was inoculated with 290 
MoDCs derived from its own PBMCs, since animals were not inbred. Subgroups were 291 
organized as summarized in Table 1. Pigs were monitored daily for immunisation 292 
reactions and samples of blood were collected at day 0 and 21. Fourteen days after the 293 
DC immunisation, pigs were euthanized with an intravenous overdose of sodium 294 
pentobarbital and blood and superficial inguinal lymph nodes (InLNs) were collected at 295 
culling.  296 
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Additionally, at the age of 4-5 weeks, four female piglets (Large White x Duroc x 297 
Pietrain) were divided in 2 groups, E and F (Table 1). Two piglets (E) were SC 298 
inoculated once into right inguinal zone with SPIO-MoDCs (approx. 5 x 10
5
/mL viable 299 
labelled DCs) and two additional piglets (F) with RHDV-3A-VLP pulsed SPIO-MoDCs 300 
6 days after blood collection. One piglet of group E was used for MRI tracking in vivo 301 
and group E was sacrificed two days after the MoDC injection. Group F was sacrificed 302 
one week after MoDC inoculation. At culling of group E and F blood and InLNs were 303 
collected for histological and immunological studies (Fig. 7 supplementary data). 304 
The experiment received prior approval from the Ethics committee for Animal 305 
Experimentation of the Institution (Universitat Autònoma de Barcelona, permit number: 306 
1189). The treatment, housing and husbandry conditions conformed to the European 307 
Union Guidelines (The Council of the European Communities 1986, EU directive 308 
86/609/EEC). All efforts were made to minimize animal suffering.  309 
 310 
2.9 In vivo dendritic cell tracking with MRI  311 
For MRI in vivo tracking, a 4-5 week old piglet (approx. 12 kg) was used. PBMCs were 312 
collected at D0 and poMoDCs were generated as described above. At day 5 poMoDCs 313 
were incubated overnight with SPIO at 50 μg Fe/mL and around 5 x 105/mL viable 314 
SPIO-MoDCs were injected SC into the right inguinal zone at day 6. MRI of the 315 
draining LN regions was acquired under anaesthesia at different times prior and post 316 
MoDC injection. The pig was anesthetized with 5 mL of azaperone (Stresnil®) and 317 
ketamine (Imalgene®) mixed solution and maintained with isoflurane anesthesia during 318 
MRI scans. MRI was performed before inoculation (basal MRI) and after 20 minutes, 319 
30 and 46 h post inoculation. The pig was imaged using a 0.18 T magnetic resonance 320 
system (Vet-MR, Esaote, Genova, Italy) with a knee coil for signal reception, in dorsal 321 
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recumbency. MRI was obtained with a gradient echo pulse sequence; T2*-weighted 322 
transverse images were acquired with an echo time of 14 ms, repetition time 410 ms, 323 
flip angle 30º, 4.4 mm slice thickness and an average total acquisition time of 7 min and 324 
29 seconds. At 48 h post inoculation the pig was euthanized and InLNs were used for 325 
histological studies and Prussian blue staining. 326 
 327 
2.10 Staining and immunohistochemistry of histopathological sections 328 
Left and right InLNs were fixed in 10% buffered formalin and routinely processed for 329 
histopathology. Sections 3 m thick were cut, stained with hematoxylin and eosin (H-E) 330 
and observed in a blinded-fashion method. Reactivity in each InLN was evaluated by 331 
means of a semi-quantitative score taking into account the percentage of secondary 332 
follicles in the whole InLN section; the following scoring was used: 0-5% (-), 0-30% 333 
(+), 30-70% (++), 70-100% (+++). 334 
Additionally, cell culture or tissue sections were stained with Prussian blue (Perls’ 335 
staining) to detect SPIO-labeled cells. Briefly, slides were stained with 2% potassium 336 
hexacyanoferrate (II)-trihydrate in 0.2 M HCl for 30 min and counterstained with eosin. 337 
The amount of positive cells was measured using digital morphometry software 338 
(ImageJ). Two sections were analyzed for each lymph node, and for each section, three 339 
low power fields (10x) were randomly selected. The percentage of area occupied by 340 
positive cells was calculated for each field. 341 
Finally, immunohistochemistry was performed using antibodies against MAC387 342 
(1:500, DAKO) and CD163 (Neat, INIA, Spain) incubated overnight at 4°C. 343 
Subsequently, both antibodies were incubated with EnVision
®
+ System-HRP (DAKO) 344 
for 45 min at room temperature and revealed with diaminobenzidine-hydrogen peroxide 345 
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solution for 10 min. Finally, slides were additionally stained using Prussian blue as 346 
described above. 347 
 348 
2.11 ELISPOT assay 349 
One or two weeks after immunisation, PBMCs and InLN cells were collected and 350 
analyzed for specific IFN-γ production by ELISPOT following manufacturer’s 351 
instructions (Becton Dickinson, UK). Briefly, PBMCs were isolated by Histopaque-352 
1.077® gradient and plated in duplicate at 5 x 10
5
/100 μL/well in RPMI-1640 353 
supplemented with 10% foetal calf serum (FCS) into 96-well plates (MultiScreen® 354 
MAHAS4510 Millipore). InLN cells were isolated in PBS using scalpel and scissors, 355 
passed through 70 and 45 μm filters and plated in duplicate at 104 and 103/100 μL/well. 356 
Plates were coated overnight at 4ºC with 5 μg/mL anti-pig IFN-γ-specific capture mAb 357 
(P2G10, Becton Dickinson UK) 100 μL/well. For the in vitro antigen recall, 35 μg/mL 358 
of 3A peptide or 20 μg/mL of RHDV-VLPs and RHDV-3A-VLPs were used as stimuli. 359 
As positive control, cells were incubated with 10 μg/mL phytohaemagglutinin (PHA) 360 
(Sigma) and cells incubated in the absence of antigen were used as negative control. 361 
Plates were cultured for 72 h at 37ºC, then incubated with 2 μg/mL of biotinylated anti-362 
IFN-γ mAb (P2C11, Becton Dickinson), followed by streptavidin-horseradish 363 
peroxidase conjugates (Jackson Immunoresearch Lab.). The presence of IFN-γ-364 
producing cells was visualised using 3-Amino-9-Ethylcarbazole (AEC) substrate 365 
(Sigma). The background values (number of spots in negative control wells) were 366 
subtracted from the respective counts of the stimulated cells and immune responses 367 
were expressed as number of spots per million of PBMCs or InLN cells. Data are 368 
representative of two different assays performed with the samples. 369 
 370 
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2.13 Statistical analysis 371 
All statistical analysis was performed using SPSS 15.0 software (SPSS Inc., Chicago, 372 
IL, USA). For all analyses, each pig was used as the experimental unit. The significance 373 
level (α) was set at 0.05 with statistical tendencies reported when P<0.10. A non-374 
parametric test (Kruskal-Wallis) was chosen to compare the different values obtained 375 
for the immunological parameters and histopathological scores between groups in the 376 
different experiments. This non-parametric analysis was chosen due to the number of 377 
animals used in each experimental group. Finally, a Fisher exact test was used to test the 378 
association between histopathological observations (presence or absence of secondary 379 
lymphoid follicles) and the experimental group.  380 
 381 
3. Results 382 
 383 
3.1 Phenotype and functional characterization of SPIO-labelled MoDCs 384 
To assess the question of whether SPIO labelling procedure and the engulfed iron may 385 
cause any changes in the viability and immunological properties of the poMoDCs, 386 
different functional assays were performed in vitro. Firstly, titration experiments were 387 
performed to test the effect of SPIO particles in mature MoDC culture. Labelling of 388 
poMoDCs with SPIO altered in some way poMoDCs viability; in fact, mortality around 389 
30% was observed by trypan blue and by flow cytometry when poMoDCs were 390 
incubated with 12-50 µg Fe/mL (Fig. 1A). Similar values were obtained when human 391 
MoDCs were incubated with 200 µg Fe/mL SPIO (Fig. 1B), meaning that around 70% 392 
of the porcine SPIO-MoDCs were viable in the culture.  393 
On the other hand, labelling efficiency using 25 µg Fe/mL was around 95%, as shown 394 
by Perls staining of SPIO-poMoDC culture (Supplementary data Fig. 8, 4). Thus, a 395 
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range between 25 and 50 µg Fe/mL of SPIO concentration was considered appropriate 396 
for in vitro and in vivo studies. At day 6, SPIO-poMoDCs morphology was consistent 397 
with previous studies in other porcine (Peng et al., 2013) or murine (Baumjohann et al., 398 
2006) cells, with clustered brownish particles in the cell cytoplasm (Supplementary data 399 
Fig. 8A, 2-3). The phenotype of poMoDCs was consistent with previous studies 400 
(Carrasco et al., 2001; Crisci et al., 2012b) and the phenotype of SPIO-labelled and 401 
unlabelled poMoDCs appeared quite similar and consistent with mature poMoDCs, 402 
except for the expected SPIO labelled-cell complexity enhancement showed by the SSC 403 
(Fig. 2A). Flow cytometry analysis of all markers revealed no statistically significant 404 
changes in the surface expression of molecules involved in antigen capture (CD163), 405 
presentation (MHC class II, I) and co-stimulation (CD80/86) between mock/unlabelled 406 
MoDCs and SPIO-MoDCs. Only a slightly decrease in surface markers intensity was 407 
visible in SPIO culture comparing with mock DCs (Fig. 2A). Phenotype of SPIO-408 
MoDCs was similar to mock MoDCs after LPS stimulation and up-regulation of SLAII 409 
(data not shown) and CD80/86 (Fig. 2A) was observed in both cultures. 410 
Similar results were obtained testing SPIO in huMoDCs (Supplementary data Fig. 8). 411 
SPIO labelled huMoDCs showed brownish cytoplasmatic particles (Supplementary data 412 
Fig. 8A) and maintained the expression of cell surface markers as mock culture (Fig. 413 
3A). This phenotype was consistent with mature huMoDCs. SPIO concentration of 200 414 
µg Fe/mL used for huMoDCs was previously established in (de Vries et al., 2005) to be 415 
optimal in terms of viability and cell labelling. Nevertheless, additional viability testing 416 
was performed in huMoDCs using SPIO at 200 µg Fe/mL and the results showed that 417 
cell viability was around 70% (Fig. 1B). 418 
Cytokine production was determined in supernatants of both mock and SPIO-poMoDCs 419 
cultured in the presence or absence of RHDV-3A-VLPs or LPS at 24 h. TNF-α 420 
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production was similar (p>0.05) between SPIO-labelled and unlabelled poMoDCs (Fig. 421 
2B) in the range of 25-50 μg Fe/mL of SPIO. The same pattern was obtained with IL-6 422 
(data not shown). Finally, using MLR test, the functionality of poSPIO-MoDCs 423 
compared with mock cells was evaluated. Both poMoDC cultures induced similar PBLs 424 
proliferation pattern when incubated alone or with RHDV-3A-VLP for 4 days (Fig. 425 
2C).  426 
Likewise, human SPIO labelled MoDCs maintained their functionality as revealed by 427 
MLR assay measuring proliferation (Fig. 3B) and IFN-production (Fig. 3C). 428 
Statistically significant differences between groups (p>0.05) were not observed. 429 
Together these results demonstrated that SPIO labelling did not affect DC functionality, 430 
being a suitable candidate for in vivo cell tracking. 431 
 432 
3.2 In vivo MRI tracking 433 
Because the functional assays described above did not show strong reductions in the 434 
immunological key features of MoDCs by labelling procedures, poSPIO-MoDCs were 435 
used for in vivo MRI detection after their SC inoculation. Small hypointense signals or 436 
signal voids could be observed in the right inguinal subcutaneous tissue at all three time 437 
points post inoculation. Similarly, multifocal signal voids up to 3.8 mm in diameter 438 
were present in the right and left inguinal lymph nodes. The signal voids were already 439 
present in the right lymph node at 20 min, and they were visible in both lymph nodes, 440 
although being always larger in the right one at 30 h and 46 h (Fig. 4, arrows).  441 
 442 
3.3 Histology and immunohistochemistry of regional lymph nodes 443 
In pigs, lymphoid follicles are located in the center of the lymph node, rather than in the 444 
periphery as in the rest of domestic animals (Fig. 5A). These can be observed in figure 445 
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5B, where few secondary follicles are indicated by arrows. In figure 5C, higher 446 
numbers of secondary follicles are observed. Histopathological analysis of the 447 
superficial InLNs revealed some grade or reactivity in the lymph nodes in all the 448 
experimental groups (in a range of 33 to 66% of the animals) with the exception of the 449 
control group (0%). No statistically significant differences were observed between 450 
experimental groups, probably due to low statistical potency of the experimental design 451 
(2 or 3 animals by group) (Table 2).  452 
Additionally, localization of SPIO-labelled DCs in the InLNs was further confirmed by 453 
histology after Prussian blue staining of sections (Fig. 5). Piglets inoculated with SPIO 454 
labelled DCs showed iron-containing cells in the paracortex and subcapsular area of 455 
both InLNs (Fig. 5 D, E). Moreover, piglets inoculated with RHDV-3A-VLP pulsed 456 
SPIO-MoDCs showed higher level of Prussian blue positive cells (Fig. 5D left InLN 457 
and 5E right InLN). Higher positivity correlated to higher SPIO concentration used for 458 
labelled DC generation (Table 2). Similar pattern was observed in the InLNs from pig 459 
monitored by MRI (data not shown). 460 
One question was whether or not SPIO-containing cells in the lymph nodes were 461 
macrophages that had phagocytosed SPIO-poMoDC or cell-free SPIO particles released 462 
from dead cells. The results in figure 5 showed that the majority of SPIO-containing 463 
cells were negative for bona fide macrophage markers as MAC387 (Chianini et al., 464 
2001) and CD163 (Bullido et al., 1997) (Fig. 5, F and G respectively), indicating that 465 
SPIO-positive cells were not macrophages and suggesting that they were SPIO-MoDCs.  466 
 467 
3.4 DC immunization stimulate specific systemic and local responses 468 
To get insight into the possibility to use pigs as model for DC-based immunization test, 469 
local and systemic cell-mediated responses induced by RHDV-3A-VLP and RHDV-470 
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VLP-pulsed MoDCs immunization were studied. PBMCs or InLN cells were tested one 471 
or two weeks after immunization for studying systemic and local responses 472 
respectively. In the case of systemic responses, two weeks after the DC immunization of 473 
animals with RHDV-3A-VLP, specific IFN-γ-secreting cells against peptide 3A were 474 
detected in PBMCs from RHDV-3A-VLP pulsed MoDC group by ELISPOT (Fig. 6). 475 
As expected, animals in the RHDV-VLP pulsed MoDC group did not show any specific 476 
3A response (Fig. 6). Unsurprisingly, animals treated with RHDV-3A-VLP or with 477 
RHDV-VLP pulsed MoDC showed IFN-γ-secreting cells against RHDV-VLP and 478 
RHDV-3A-VLP (Fig. 6). Animals treated with RHDV-VLP pulsed MoDC showed 479 
higher response compared to animals treated with RHDV-3A-VLP pulsed MoDC after 480 
RHDV-VLP stimulation (Fig. 6). 481 
Analysis of local responses in InLN revealed that animals treated with RHDV-3A-VLP 482 
or with RHDV-VLP pulsed MoDC were able to induce higher number of specific IFN-483 
γ-secreting InLN cells against RHDV-VLP and RHDV-3A-VLP comparing to unpulsed 484 
animals (Fig. 6). An interesting finding was that RHDV-3A-VLP pulsed SPIO-MoDC 485 
immunization was also able to induce specific systemic and local responses against all 486 
the antigens used in the ELISPOT assay (Fig. 6). No statistically significant differences 487 
were observed between experimental groups, probably due to low statistical potency of 488 
the experimental design (2 or 3 animals by group). As expected, in all the assays, 489 
control pigs and unpulsed-MoDC-immunized pigs did not show any significant 490 
response or background level. 491 
 492 
4. Discussion 493 
In vivo serial tracking of porcine SPIO mesenchymal stem cells (MSCs) can be 494 
achieved by MRI and miniature Tibetan swine, which have shown to be ideal animals 495 
21 
 
for researching heart function (Yang et al., 2011). However, no studies so far have 496 
addressed tracking SPIO-loaded DC in pigs. To the best of our knowledge, this is the 497 
first report of tracking of SPIO-labelled DCs in pigs by non-invasive MRI technology, 498 
which was confirmed by histology. Interestingly, antigen-loaded SPIO-DCs were 499 
located with the draining lymph nodes and they were able to induce specific immune 500 
responses after cell administration. 501 
 502 
In our study, porcine MoDCs were labelled in the immature state, when they are highly 503 
phagocytic (Banchereau and Steinman, 1998), increasing the probability of intracellular 504 
magnetic labelling with SPIO particles. The most effective iron concentration for 505 
labelling porcine DCs led to an optimal ratio of 25-50 µg Fe/mL in our system. The 506 
phenotype and functional properties of the SPIO-labelled DCs were slightly altered as 507 
compared with unlabelled DCs. Our work was in line with a previous study performed 508 
in mice (de Chickera et al., 2011). Nevertheless, any changes in other parameters tested 509 
such as cytokine production and T cell activation (as T cell proliferation) could not be 510 
observed, confirming in vitro the functionality of SPIO-MoDCs. Thus, having shown 511 
that pig-derived DCs can be labelled with SPIO without affecting its functional 512 
properties, further studies were conducted to follow the migration of autologous ex vivo-513 
cultured SPIO-MoDCs after subcutaneous administration into the inguinal zone of pigs. 514 
SPIO-MoDCs were tracked in vivo by MRI to determine their migratory behaviour after 515 
subcutaneous injection.   516 
The major advantage of MRI is a superior anatomical correlation and spatial resolution, 517 
which allows precise localization of SPIO-labelled DCs at the actual injection site and 518 
after migration. Although in vivo imaging provided us with a lot of information on the 519 
distribution of the DC immunization after injection, technical restrictions limited the 520 
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results in porcine lymph nodes to be positive/negative for cell-tracking label, as it was 521 
also previously described in human by Verdijk et al. (Verdijk et al., 2009). In fact, the 522 
low resolution of the MR used in this study was not sufficient for monitoring the precise 523 
localization of SPIO-DCs. These results paved the way for future studies with higher 524 
MRI resolution to analyse DC interaction within lymph nodes in more detail.  525 
Specific signal in the lymph node was detected after subcutaneous injection of around 526 
half a million of SPIO-MoDCs. Thus, this technological approach was able to detect a 527 
relative low amount of labelled-DCs in the InLN, which we were not able to quantify. 528 
However, previous studies have shown that after intradermal injection hardly 4% of 529 
DCs migrated to the draining lymph nodes (Verdijk et al., 2009) and after subcutaneous 530 
injection only the 1-2% (Baumjohann et al., 2006; MartIn-Fontecha et al., 2003). If this 531 
percentage were to be applied in our experimental conditions in swine, MRI would be 532 
able to detect around 5,000-10,000 labelled cells in superficial InLNs. The pattern of the 533 
labelling from those studies compared to the one presented here was rather similar, as 534 
shown in (Fig.  4, 5, (Baumjohann et al., 2006)) and probably it was due to the fact that 535 
InLNs are very superficial and the migration from the site of inoculation was very rapid, 536 
as confirmed by the MRI performed 20 min after administration. Furthermore, higher 537 
signal from SPIO pulsed DC was detected in the right InLN (closest to the inoculation 538 
site) but signal voids were also present in the left one.  539 
The fact that pig can be used as model for testing DC tracking in vivo is particularly 540 
relevant. Further optimization for cell-based therapies in human is required but the data 541 
presented here the proof of concept. In fact, domestic pigs represent an excellent animal 542 
model for immunological studies, since they are outbred animals that better resemble 543 
the variability of human population and experiments in pigs are much more likely to be 544 
predictive of therapeutic treatments in humans than experiments in rodents. In vivo 545 
23 
 
following of therapeutic cells primarily tracks the cell label and may need to be 546 
confirmed with immunohistochemical studies. Depending on the method of 547 
administration and the nature of the vaccine, immunohistochemical analysis of target 548 
organs will still be decisive for quantitative and qualitative evaluation of the efficacy of 549 
cellular therapy (Verdijk et al., 2009).  550 
Subsequently, histological analysis and Prussian blue staining of porcine tissue sections 551 
from dissected lymph nodes was used to visualize SPIO-labelled cells offering further 552 
validation to track mixed cell populations at single-cell level, something that cannot be 553 
possible in the case of human trials. The data in this study revealed that paracortex and 554 
subcapsular areas of the lymph node were positive for Prussian blue staining and the 555 
presence of SPIO-labelled DCs correlated with the concentration of iron particles used 556 
during DC generation. This location resembled the one reported in previous DC 557 
migration studies performed in human (de Vries et al., 2005) and mice (Baumjohann et 558 
al., 2006). Additionally, the pattern of immunohistochemistry staining have shown that 559 
the majority of the Perls
+
 cells were not from bona fide macrophage markers, suggesting 560 
that they might indeed correspond to injected pulsed DCs and the signal was mainly not 561 
due to macrophages that had phagocytosed cell-free SPIO particles released from dead 562 
cells or SPIO pulsed DC. However, a small percentage of phagocytosis of free SPIO 563 
particles or dead SPIO
+
 cells by APC cannot be excluded to occur in this system.  564 
Once it was shown that pulsed DC were functional in vitro and they were able to 565 
migrate from the site of injection to the regional lymph nodes, the question to answer 566 
was whether these pulsed DC were able to elicit a specific immune response.  567 
Production of specific IFN-γ producing cells against the vector (RHDV-VLPs) and also 568 
against the antigenic epitope inserted into the VLPs (3A) after one or two weeks post 569 
inoculation was shown (Fig. 6). These results indicated that these pulsed DC were 570 
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functionally active in vivo. Despite of the lack of statistical significance of the data, pigs 571 
were able to induce not only specific local and but also systemic responses.  572 
In this study, subcutaneous inoculation was used since it is one of the most frequently 573 
route used to treat solid tumors in human (Verdijk et al., 2009) and also because it 574 
allowed us to track the cells in accessible lymph nodes in pigs. Nevertheless, other 575 
routes or combination of them may be tested in further studies using higher resolution 576 
MRI. 577 
In conclusion, this is the first study demonstrating the potential of using MRI for 578 
tracking DCs in pigs and showed how these animals represent an excellent and closer 579 
animal models to human than rodents to monitor and optimize DC-based therapies. The 580 
results in this proof-of-principle study pave the way to use pig as model for a variety of 581 
DC studies in vivo, which might be of pivotal importance for cell immunotherapy in 582 
humans in the future. 583 
 584 
 585 
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 601 
6. Conclusions 602 
 Human or pig dendritic cells pulsed with superparamagnetic iron oxide particles 603 
did not alter their phenotypic and functional properties in vitro in the 604 
experimental conditions tested in this work.   605 
 After subcutaneous inoculation in pigs, porcine SPIO-MoDC migration to 606 
regional lymph nodes was detected by MRI and confirmed by Perls staining of 607 
draining lymph nodes.  608 
 Only one dose of virus-like particles-pulsed MoDCs in pigs was able to induce 609 
specific local and systemic responses. 610 
 This proof-of-principle study shows the potential of using pigs as a suitable 611 
animal model to test DC trafficking with the aim of improving cellular therapies. 612 
 613 
 614 
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8. Figure legends 744 
 745 
Fig. 1.Viability test of SPIO labeled porcine and human MoDCs.  746 
Viability of SPIO-MoDCs was assessed by flow cytometry using LIFE/DEAD Fixable 747 
Dead Cell Stain Kit and FITC-conjugated Annexin V. (A) PoMoDCs were incubated 748 
with 50 μg Fe/mL of SPIO particles. This is a representative experiment from two 749 
independent experiments performed using poMoDCs from two different animals. Gate 750 
strategy is showed in a representative plot. (B) HuMoDCs were incubated with SPIO at 751 
200 μg Fe/mL. This is a mean+SD from two independent experiments performed using 752 
HuMoDCs generated from two different donors. Gate strategy is showed in a 753 
representative plot.  754 
 755 
Fig. 2. Morphology and phenotype of SPIO-labelled porcine dendritic cells. 756 
A) Phenotype of porcine SPIO-MoDCs compared with mock culture at day 6. Similar 757 
patterns for CD172a, SLAII, CD163 and CD80/86 molecules were observed when 758 
MoDCs were incubated with a range of 25-50 μg Fe/mL of SPIO particles. Light grey 759 
histogram shows the isotype control. After LPS stimulation, the up-regulation of 760 
CD80/86 marker (black line) was consistent in SPIO-MoDCs and mock culture. Dark 761 
grey histograms with dotted line show the marker expression in un-stimulated DCs and 762 
light grey the isotype control.  B) Cytokine production after LPS and RHDV-3A-VLP 763 
stimulation. TNF-α production in SPIO-MoDCs (30 μg Fe/mL) (black histograms) and 764 
mock culture (white histograms) at 24 h. C) Mixed lymphocyte reaction. Effect on 765 
PBLs activation by pulsed MoDCs. Untreated MoDCs (white) and SPIO-MoDC (black) 766 
were co-cultured with allogeneic PBLs (ratio 1:20, respectively). Four days after, co-767 
culture proliferation was evaluated using CFSE. PBLs co-cultured with mock MoDCs 768 
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or SPIO-MoDCs were used as negative control. Data represents the mean ± SD (n = 4) 769 
and are representative of three independent experiments with different animals. 770 
 771 
Fig. 3. Morphology, phenotype and immunogenicity of SPIO-labelled human 772 
dendritic cells. 773 
A) Phenotype of human SPIO-MoDCs compared with mock culture at day 7. Similar 774 
expression patterns for CD80, CD83, CD86 and HLA-DR molecules were observed 775 
when huMoDCs were incubated with 200 μg/mL of SPIO particles. Grey histogram 776 
shows the isotype control. B) Mixed lymphocyte reaction. Untreated HuMoDCs (black) 777 
and SPIO-huMoDC (grey) were co-cultured with allogeneic PBLs (ratio 1:20, 778 
respectively). Six days after, co-culture proliferation was evaluated using tritiated 779 
thymidine. C) IFN-γ production by T cells was tested in the supernatant of MLR using 780 
ELISA. Data represents the mean ± SD of triplicates and are representative of four 781 
independent experiments with different donors (n = 4).  782 
 783 
Fig. 4. MRI of superficial inguinal lymph nodes and site of inoculation.  784 
SPIO-MoDCs inoculated pig from group E using 50 μg Fe/ml. T2* Transverse MRI 785 
slices at the level of the InLNs and the site of inoculation before the inoculation (A), 20 786 
minutes (B), 30 h (C) and 46 h (D) after inoculation. At the site of inoculation, small 787 
signal voids are visible in the right subcutaneous tissue (arrow), being more evident 20 788 
min after inoculation but still visible 30 h and 46 h after inoculation. A) Before 789 
inoculation, the InLNs appear as two oval areas (arrows) that show a hyperintense 790 
signal compared to the surrounding inguinal fat. Note that the right InLN is larger than 791 
the left. B) 20 min after inoculation, an oval signal void (arrow) is visible within the 792 
lateral aspect of the right InLN. C) 30 h after inoculation, multiple small signal voids 793 
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(arrows) are also present in the left InLN, which appears more symmetrical with the 794 
right than in the previous images. D) 46 h after inoculation, an oval signal void (arrow) 795 
is still visible within the lateral aspect of the right InLN, whereas no signal voids are 796 
visible in the left InLN in this slice. Note: Ventral is to the top, and right is to the left.   797 
 798 
Fig. 5. Histopathological analysis of porcine superficial inguinal lymph nodes.  799 
A) Haematoxylin and eosin (H-E), superficial InLN from a control animal (grade -). B) 800 
H-E, there are small numbers of secondary lymphoid follicles (arrows) (grade +) (group 801 
A). Bar = 100 μm. C) H-E, moderate numbers of secondary lymphoid follicles (arrows) 802 
(grade ++) (group D). Bar = 100 μm. D) Perls stain, moderate number of positive cells 803 
(grade ++) in subcapsular and paracortical areas (left InLN group F). Bar = 100 μm. E) 804 
Perls stain, large numbers of positive cells (grade +++) in subcapsular and paracortical 805 
areas (right InLN group F). Bar = 100 μm. F) Immunohistochemistry, positive cells for 806 
MAC387 antibody (brown) are different from those Prussian blue positive cells (blue) 807 
(group F). Bar = 100 μm. Inset: particular of MAC+ cells and SPIO staining with higher 808 
magnification, bar = 20 μm. G) Immunohistochemistry, the majority of positive cells 809 
for CD163 antibody (brown) are different from those Prussian blue positive cells (blue) 810 
(group F). Bar = 100 μm. Inset: particular of Perls+ cells and CD163+ cells with higher 811 
magnification, bar = 20 μm. 812 
 813 
Fig. 6. ELISPOT IFN-γ assay. 814 
Specific local and systemic cellular responses of RHDV-3A-VLP pulsed MoDC and 815 
RHDV-3A-VLP pulsed SPIO-MoDC immunised pigs against the vector RHDV-VLP, 816 
against the peptide 3A and against chimeric RHDV-3A-VLP at day 7 and 14. Pigs are 817 
divided in different groups, depending on the different MoDCs: RHDV-3A-VLP-pulsed 818 
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MoDCs (A), RHDV-VLP-pulsed MoDCs (B), control animals (C), unpulsed MoDCs 819 
(D) and RHDV-3A-VLP-pulsed SPIO-MoDCs (F). Specific RHDV-VLP, chimeric 820 
RHDV-3A-VLP and 3A IFN-γ-producing cells are detected by ELISPOT. The 821 
background values (number of spots in negative control wells) were subtracted from the 822 
respective counts of the stimulated cells and the immune responses were expressed as 823 
number of spots per million of PBMCs or InLN cells for each animal. Shown are the 824 
results of duplicate wells for representative data of two repeated experiments.  825 
 826 
Fig. 7. Supplementary data. Study design.  827 
Porcine peripheral blood mononuclear cells (PBMCs) were obtained from pigs and 828 
monocyte-derived dendritic cells (poMoDCs) where generated by a five-day protocol. 829 
PoMoDCs were cultured and labelled with SPIO particles. Then SPIO-DCs were 830 
injected subcutaneously into the right inguinal zone and their migration was monitored 831 
in vivo by MRI of regional lymph nodes. Superficial regional inguinal lymph nodes 832 
were obtained after culling and histological studies were performed using Perls staining 833 
or immunohistochemistry. 834 
 835 
Fig. 8. Supplementary data. 836 
A) Morphology of porcine MoDCs culture with and without SPIO. A1: Morphology of 837 
poMoDCs at day 6 of culture. Original magnification 200x. A2: Morphology of porcine 838 
SPIO-MoDCs at day 6 of culture using 25-50 μg Fe/mL of SPIO particles. Original 839 
magnification 200x. A3: SPIO-poMoDCs in phase contrast image, original 840 
magnification 400x. A4: Perls staining of SPIO-poMoDC culture with 25 μg Fe/mL of 841 
SPIO particles. Bar = 25 μm.  B) Morphology of human SPIO-MoDCs at day 6 of 842 
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culture using 200 μg/mL of SPIO particles. Phase contrast image, original magnification 843 
200x. 844 
 845 
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Table 1. In vivo experimental designs. 1 
 2 
SC: subcutaneous injection; Dpi: days post immunization; Perls: Prussian Blue staining for iron particles. 3 
M: male; F: female. Weight represents the mean ± standard deviation of all animals in the group.  4 
* one animal was inoculated with 25 μg Fe/ml and the other with 50 μG Fe/ml of SPIO. 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
Group Inoculum Pigs Sex 
Age 
(weeks) 
Weight 
(kg±SD) 
Route 
Dpi/ 
Analysis 
A 
RHDV-3A-
VLP 
pulsed 
moDCs 
3 M 6-7  20.5±2.8 SC 
D14 
Local and 
systemic 
responses 
B 
RHDV-
VLP 
pulsed 
moDCs 
3 M 6-7 18±1 SC 
D14 
Local and 
systemic 
responses 
C Medium 2 M 6-7 19.3±0.4 SC 
D14 
Local and 
systemic 
responses 
D 
Un-pulsed 
moDCs 
2 M 6-7 18.8±1.8 SC 
D14 
Local and 
systemic 
responses 
E 
SPIO-
moDCs 
2* F 4-5 12.2±0.8 SC 
D2 
MRI and Perls 
F 
RHDV-3A-
VLP pulsed  
SPIO-
moDCs 
2* 
 
F 4-5 13.4±1.1 SC 
D7 
Local and 
systemic 
responses, Perls 
Table 1
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Tabla 2.  Histopathological score of superficial inguinal lymph nodes.  1 
 2 
Animal H-E Perls 
A1 + NP 
A2 - NP 
A3 + NP 
B1 + NP 
B2 - NP 
B3 - NP 
C1 - - 
C2 - - 
D1 - - 
D2 ++ - 
E1 - 0,27 (50) 
E2 + 0,21 (25) 
F1 - 3,53 (50) 
F2 - 1,54 (25) 
 3 
H-E. The reactivity of the InLNs was evaluated taking into account the percentage of secondary cortical 4 
follicles regarding the whole LN; the following scoring was used: 0-5% (-), 0-30% (+), 30-70% (++), 70-5 
100% (+++). Perls: The amount of positive cells was measured using digital morphometry software 6 
(ImageJ). Two sections were analyzed for each lymph node, and for each section, three low power fields 7 
(10x) were randomly selected. In each field, the percentage of area occupied by positive cells was 8 
calculated. The table expresses the average of these measures. (50 or 25) indicate the SPIO μg Fe/ml  9 
inoculated in the animal; (-) negative; NP: not performed. 10 
 11 
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